Aegle Therapeutics
Latest round
- Series A
Last raised
- Sep 2020
Total raised
- $11M
Investors
- 5
About Aegle Therapeutics
Aegle Therapeutics Corp., founded in 2019 and headquartered in Miami, US, specializes in developing innovative therapies using extracellular vesicles (EVs).Aegle Therapeutics specializes in regenerative medicine by developing innovative extracellular vesicle (EV) therapies aimed at treating debilitating rare diseases, particularly dystrophic epidermolysis bullosa (DEB) and other severe dermatological disorders. Their core product, AGLE-102, is a therapeutic composite of EVs, including exosomes derived from mesenchymal stem cells (MSCs), which utilize proprietary EV harvesting technology. This product is designed to deliver biomolecular payloads capable of stimulating cellular functions and promoting healing in affected individuals. The company’s clinical-stage offerings are targeted primarily at patients with significant unmet medical needs in North America and Europe, with an active phase 1/2 clinical study for AGLE-102 currently open for enrollment among individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB).Aegle Therapeutics operates within a clinical development framework, focusing on the commercialization of its EV-based therapies. Revenue generation occurs primarily through partnerships with healthcare providers, hospitals, and research institutions engaged in clinical trials and subsequent product implementations. Given the clinical nature of their offerings, transactions typically involve agreements structured around clinical trial sponsorships and potential future sales of AGLE-102 upon successful completion of regulatory pathways. As the company progresses through its clinical trials and works towards market launch, it anticipates revenue streams would primarily arise from direct engagements with healthcare institutions, potentially accompanied by future collaborations with pharmaceutical companies for broader distribution. The company is focused on advancing its clinical trials for AGLE-102 and aims to broaden its reach into North America and Europe, targeting specific healthcare institutions for collaborations by 2022.
Who invested in Aegle Therapeutics
5 investors across 2 rounds
See all investors in Aegle Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aegle Therapeutics
Who invested in Aegle Therapeutics?
Aegle Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aegle Therapeutics raised?
Aegle Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aegle Therapeutics last raise money?
Aegle Therapeutics's most recent round on record is a Series A, in Sep 2020.
What does Aegle Therapeutics do?
Aegle Therapeutics is a healthcare specialists company.
Where is Aegle Therapeutics headquartered?
Aegle Therapeutics is headquartered in Miami, US.
Which VCs invest in companies like Aegle Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare specialists companies at Aegle Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series A
Raising like Aegle Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.